Next Article in Journal
Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease
Previous Article in Journal
Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma
 
 
Article

Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study

1
Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Epidemiology & Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China
2
Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, 6229 ER Maastricht, The Netherlands
3
State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, Southeast University, Nanjing 210096, China
4
Nanjing EVLiXiR Biotechnology Co., Ltd., Nanjing 210032, China
5
Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China
6
Westlake Intelligent Biomarker Discovery Laboratory, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China
7
Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China
8
Medical School of Southeast University, Nanjing 210009, China
9
Key Laboratory of Environmental Medicine Engineering, School of Public Health, Southeast University, Ministry of Education, Nanjing 210009, China
10
School of Nutrition and Translational Research in Metabolism, Maastricht University, 6229 ER Maastricht, The Netherlands
11
Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing 210009, China
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(8), 5442-5456; https://doi.org/10.3390/curroncol29080430
Received: 1 July 2022 / Revised: 23 July 2022 / Accepted: 25 July 2022 / Published: 31 July 2022
(This article belongs to the Section Genitourinary Oncology)
Objectives: The molecular landscape of non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer based on molecular characteristics is essential but poorly understood. In this pilot study we aimed to identify a multi-omics signature that can distinguish MIBC from NMIBC. Such a signature can assist in finding potential mechanistic biomarkers and druggable targets. Methods: Patients diagnosed with NMIBC (n = 15) and MIBC (n = 11) were recruited at a tertiary-care hospital in Nanjing from 1 April 2021, and 31 July 2021. Blood, urine and stool samples per participant were collected, in which the serum metabolome, urine metabolome, gut microbiome, and serum extracellular vesicles (EV) proteome were quantified. The differences of the global profiles and individual omics measure between NMIBC vs. MIBC were assessed by permutational multivariate analysis and the Mann–Whitney test, respectively. Logistic regression analysis was used to assess the association of each identified analyte with NMIBC vs. MIBC, and the Spearman correlation was used to investigate the correlations between identified analytes, where both were adjusted for age, sex and smoking status. Results: Among 3168 multi-omics measures that passed the quality control, 159 were identified to be differentiated in NMIBC vs. MIBC. Of these, 46 analytes were associated with bladder cancer progression. In addition, the global profiles showed significantly different urine metabolome (p = 0.029), gut microbiome (p = 0.036), and serum EV (extracellular vesicles) proteome (p = 0.039) but not serum metabolome (p = 0.059). We also observed 17 (35%) analytes that had been developed as drug targets. Multiple interactions were obtained between the identified analytes, whereas for the majority (61%), the number of interactions was at 11–20. Moreover, unconjugated bilirubin (p = 0.009) and white blood cell count (p = 0.006) were also shown to be different in NMIBC and MIBC, and associated with 11 identified omics analytes. Conclusions: The pilot study has shown promising to monitor the progression of bladder cancer by integrating multi-omics data and deserves further investigations. View Full-Text
Keywords: bladder cancer; multi-omics; progression of disease; molecular epidemiology bladder cancer; multi-omics; progression of disease; molecular epidemiology
Show Figures

Figure 1

MDPI and ACS Style

Yu, E.Y.-W.; Zhang, H.; Fu, Y.; Chen, Y.-T.; Tang, Q.-Y.; Liu, Y.-X.; Zhang, Y.-X.; Wang, S.-Z.; Wesselius, A.; Li, W.-C.; Zeegers, M.P.; Xu, B. Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study. Curr. Oncol. 2022, 29, 5442-5456. https://doi.org/10.3390/curroncol29080430

AMA Style

Yu EY-W, Zhang H, Fu Y, Chen Y-T, Tang Q-Y, Liu Y-X, Zhang Y-X, Wang S-Z, Wesselius A, Li W-C, Zeegers MP, Xu B. Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study. Current Oncology. 2022; 29(8):5442-5456. https://doi.org/10.3390/curroncol29080430

Chicago/Turabian Style

Yu, Evan Yi-Wen, Hao Zhang, Yuanqing Fu, Ya-Ting Chen, Qiu-Yi Tang, Yu-Xiang Liu, Yan-Xi Zhang, Shi-Zhi Wang, Anke Wesselius, Wen-Chao Li, Maurice P. Zeegers, and Bin Xu. 2022. "Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study" Current Oncology 29, no. 8: 5442-5456. https://doi.org/10.3390/curroncol29080430

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop